PatenSee closes $2M seed round, appoints seasoned CEO, expands into Michigan

Detroit, Michigan, February 20th, 2025 — PatenSee, developing a non-contact imaging device for rapid vascular access monitoring of dialysis patients, has secured a $2M first close of a seed round to advance clinical activities toward FDA approval.

The round was led by Michigan Rise with participation from Spark Capital, the Biosciences Research and Commercialization Centre (BRCC) at Western Michigan University and Edge Medical Ventures.

With financing secured, PatenSee appoints seasoned early-stage CEO and start-up veteran Paul Neeb as chief executive officer, while establishing US headquarters in Michigan towards initiating clinical trials in the US with the goal of commercial launch in 2026.

Vascular access–related complications in patients undergoing hemodialysis lead to significant patient morbidity and reduced patient quality of life. Routine monitoring remains a challenge for dialysis clinics and integration of the PatenSee technology is expected to enable early detection, and timely intervention to alleviate life threatening complications and significant financial burden.

PatenSee’s contactless monitoring system is the first to provide comprehensive physiological monitoring per KDOKI guidelines, when combined with machine learning, will alleviate the burden on dialysis clinics and transform the standard of care. The company recently initiated a clinical pilot in collaboration with Fresenius Medical Care which it now expects to expand to US sites.

Paul Neeb, chief executive officer, comments, “I am honored to lead the talented and dedicated team at PatenSee at this exciting phase of the company. We are driven to establish a new standard of care in dialysis clinics, transform patient care at a reduced cost, while alleviating the burden on clinical staff.”

“With this Seed investment, we are excited to support the innovative solutions that PatenSee is bringing to dialysis care. Their vision and commitment to improving patient outcomes position them as a leader in vascular access monitoring, and we look forward to being a part of their growth journey,” commented Jeff Wesley, Executive Director, Ventures at Michigan Rise.

About PatenSee
PatenSee is a clinical-stage medical device company developing a non-contact monitoring system for the early detection of vascular access stenosis in hemodialysis patients. Using advanced, multi-modal imaging technologies, AI and machine learning, PatenSee’s device alerts caregivers of vascular access stenosis risk at the earliest stage, enabling timely interventions to protect the patient’s hemodialysis lifeline, improve the quality of care and prolong the life of the fistula.

PatenSee was initially founded at the MEDX Xelerator, a leading MedTech venture studio supported by the Israeli innovation authority and is based in Detroit, Michigan, and Or Yehuda, Israel.

For more information, please visit patensee.com.